MTOR and head and neck squamous cell carcinoma: Based on current studies, PTEN is an emerging biomarker for recurrent HNSCC and using treatments that target the hyperactive downstream pathway (PI3K/AKT/mTOR) in combination with first-line therapies may prove to be uniquely effective in HNSCC patients with decreased PTEN expression.